Eli Lilly and Co. and Lycia Therapeutics, Inc. entered a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of targeted therapeutics using Lycia’s lysosomal targeting chimera, or LYTAC, protein degradation technology.   Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC platform may enable the development of s...